# US 2010/0166837 A1 · 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166837 A1
- Document ID: US20100166837A1
- Status: Published application
- Kind: A1
- Application number: 12/601,402
- Filed: 2008-05-23
- Published: 2010-07-01
- Earliest claimed: 2007-05-24
- Assignees: Eldrug S.A.
- Inventors: John Matsoukas
- Web page: https://patentgrep.com/patent/US20100166837A1

## CPC

- C07D 403/10: linked by a carbon chain containing aromatic rings
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds in hydrophilic or lipophilic form, which are useful as angiotensin II ATI receptor antagonists suitable for transdermal delivery. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases.

## Claims

### Claim 1

A compound of formula I,
wherein
R is H, halogen;
X is alkyl, alkenyl, —(CH2)vCOOR1 or CH═CH—(CH2)vCOOR1, where v is 0 to 10; or
R and X are linked so as to form a fused benzimidazole system;
R1 is H, alkyl, aralkyl, trityl, halogen, haloalkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, aryloxy alkoxyalkoxy, cyano, hydroxy, hydroxyalkyl, nitro, tetrazolyl, oxadiazolyl, triazolyl, OCH(CH3)—OCOO-cyclohexyl, cycloanhydride or methyl-5-methyl-[1,3]-dioxolane;
Y is H, CH2O-alkyl, CH2S-alkyl, CH2-halogen, CH2OH, CH2SH, CHO, COOH or halogen;
W1 and W2 are each independently —(CH2)n—K—Z—Z1, where n is 1 to 5;
K is biphenyl or monophenyl;
Z is tetrazolyl or COO—;
Z1 is H, trityl, halotrityl, CH2Ph, COOH, COO-alkyl or CH(Ph)2, wherein each Ph group is optionally substituted by one or more halogens; and
E is an anion;
or a pharmaceutically acceptable salt thereof.

### Claim at position 2

2-13. (canceled)

### Claim 14 (depends on 1)

A compound according to claim 1:
wherein said compound is of formula M,
wherein:
X is CH═CH—COOMe;
R is H or halogen;
Z1 is H, trityl, 2-chlorotrityl or benzyl; and
Y is as defined in claim 1; or
wherein said compound is of formula N,
wherein:
X is CH2CH2COOMe;
R is H or halogen;
Z1 is H, trityl, 2-chlorotrityl or benzyl; and
Y is as defined in claim 1; or
wherein said compound is of formula Q,
wherein:
R is H or halogen;
Z1 is H, trityl, 2-chlorotrityl or benzyl; and
Y is as defined in claim 1.

### Claim at position 4

-19. (canceled)

### Claim 20

A compound of formula II or formula III,
wherein
R is H, halogen;
X is alkenyl, —(CH2)vCOOR1 or CH═CH—(CH2)vCOOR1, where v is 0 to 10; or
R and X are linked so as to form a fused benzimidazole system; or
X is alkyl, when Z1 is halotrityl, COOH, COO-alkyl, CH2(C6H4-Hal) or CH(Ph)2, wherein each Ph group is optionally substituted by one or more halogens;
R1 is H, alkyl, aralkyl, trityl, halogen, haloalkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, aryloxy alkoxyalkoxy, cyano, hydroxy, hydroxyalkyl, nitro, tetrazolyl, oxadiazolyl, triazolyl, OCH(CH3)—OCOO-cyclohexyl, cycloanhydride or methyl-5-methyl-[1,3]-dioxolane;
Y is H, CH2O-alkyl, CH2S-alkyl, CH2-halogen, CH2OH, CH2SH, COOH, halogen or CHO;
W1 is —(CH2)n—K—Z—Z1, where n is 1 to 5;
K is biphenyl or monophenyl;
Z is tetrazolyl or COO—; and
Z1 is H, trityl, halotrityl, CH2Ph, COOH, COO-alkyl, or CH(Ph)2, wherein each Ph group is optionally substituted by one or more halogens;
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 20)

A compound according to claim 20 wherein W2 is

### Claim 22

(canceled)

### Claim 23 (depends on 20)

A compound according to claim 20 wherein n is 1.

### Claim 24 (depends on 20)

A compound according to claim 20 wherein Y is H, CH2OH, CH2OMe, CH2OEt, CH2SH, CH2SMe, COOH or halogen or CH2SEt.

### Claim 25 (depends on 20)

A compound according to claim 20 wherein R is H, Br, F, I or Cl.

### Claim 26 (depends on 20)

A compound according to claim 20 wherein Z1 is H, trityl, halotrityl, dibenzyl or benzyl.

### Claim 27 (depends on 20)

A compound according to claim 20 wherein X is CH═CH—COOR1, CH2CH2COOR1 or COOR1.

### Claim 28 (depends on 20)

A compound according to claim 20 wherein R1 is H, Me or Et.

### Claim 29 (depends on 20)

A compound according to claim 20, wherein said compound is of formula A,
wherein:
R=H or halogen;
R1=H, CH3, or —CH2CH3;
Z1=H, chlorotrityl, benzyl or trityl;
Y is as defined in claim 20.

### Claim 30 (depends on 20)

A compound according to claim 20, wherein said compound is of formula B,
wherein:
R=H or halogen;
R1=H, CH3, or —CH2CH3;
Z1=H or trityl;
Y is as defined in claim 20.

### Claim at position 16

-34. (canceled)

### Claim 35 (depends on 20)

A pharmaceutical composition comprising a compound as defined in claim 20, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable diluent, excipient or carrier.

### Claim 36 (depends on 35)

A pharmaceutical composition according to claim 35 which is in the form of a transdermal patch.

### Claim at position 19

-40. (canceled)

### Claim 41 (depends on 20)

A method of treating hypertension or a cardiovascular disorder in a subject, said method comprising administering to the subject a therapeutically effective amount of a compound according to claim 20, or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 41)

A method according to claim 41 wherein the compound is administered transdermally, subcutaneously or intravenously.

### Claim 43 (depends on 42)

A method according to claim 42 wherein the compound is administered transdermally by means of a transdermal patch.

### Claim 44

(canceled)

### Claim 45 (depends on 1)

A process for preparing a compound of formula I as defined in claim 1, said process comprising the steps of:
(i) reacting a compound of formula III with trityl chloride to form a compound of formula IIIa;
(ii) reacting said compound of formula IIIa with Br—(CH2)n—K—Z—Z1 to form a compound of formula IV;
(iii) converting said compound of formula IV to a compound of formula I.

### Claim 46 (depends on 45)

A process according to claim 45 wherein step (ii) comprises reacting said compound of formula IIIa with Br—(CH2)n—K—Z′—Z′1, wherein Z′ is tetrazoyl and Z′1 is trityl, chlorotrityl, benzyl or CH(Ph)2, to form a compound of formula IVa,
and converting said compound of formula IVa to a compound of formula I.

### Claim 47 (depends on 46)

A process according to claim 46 wherein Z′1 is trityl or benzyl.

### Claim 48 (depends on 45)

A process according to claim 45 wherein step (ii) is carried out in the presence of potassium carbonate, and the ratio of Br—(CH2)n—K—Z′—Z′1 to compound IIIa is at least 3:1.

### Claim 49 (depends on 45)

A process according to claim 45 wherein step (iii) comprises the steps of:
(iii)(a) converting said compound of formula IVa to a compound of formula IVb;
(iii)(b) treating said compound of formula IVb with 2-chlorotrityl chloride to form a compound of formula IVc;
(iii)(c) converting said compound of formula IVc to a compound of formula I.

### Claim 50 (depends on 49)

A process according to claim 49 wherein step (iii)(c) comprises treating said compound of formula IVc with formaldehyde to form a compound of formula I, wherein Y is CH2OH.

### Claim 51 (depends on 20)

A process for preparing a compound of formula II as defined in claim 20, said process comprising the steps of:
(i) reacting a compound of formula III with trityl chloride to form a compound of formula IIIa:
(ii) reacting said compound of formula IIIa with Br—(CH2)n—K—Z—Z1 to form a compound of formula V;
(iii) converting said compound of formula V to a compound of formula VI;
(iv) converting said compound of formula VI to a compound of formula II.

### Claim 52 (depends on 51)

A process according to claim 51 wherein step (ii) comprises reacting said compound of formula IIIa with Br—(CH2)n—K—Z′—Z′1, wherein Z′ is tetrazoyl and Z′1 is trityl, chlorotrityl, benzyl or CH(Ph)2, to form a compound of formula Va,
and converting said compound of formula Va to a compound of formula VIa, and converting said compound of formula VI to a compound of formula II.

### Claim at position 32

-55. (canceled)

### Claim 56 (depends on 52)

A process according to claim 52 wherein step (iv) comprises the steps of:
(iv)(a) converting said compound of formula VIa to a compound of formula VIb;
(iv)(b) treating said compound of formula VIb with 2-chlorotrityl chloride to form a compound of formula VIc;
(iv)(c) converting said compound of formula VIc to a compound of formula II.

### Claim 57 (depends on 56)

A process according to claim 56 wherein step (iv)(c) comprises treating said compound of formula VIc with formaldehyde to form a compound of formula I, wherein Y is CH2OH.

### Claim 58 (depends on 51)

A process according to claim 51 wherein steps (ii) and (iii) are carried out in a one-pot procedure.

### Claim at position 36

-60. (canceled)
